Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 707 clinical trials
Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment

  • Cytotoxicity of avelumab is mediated through antibody dependent cell cytotoxicity (ADCC) by NK cells.
  • ul>

    • 0 views
    • 19 Feb, 2024
    • 8 locations
    • 0 views
    • 26 Sep, 2024
    • 1 location
    change - Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (TOP-N53-02)  

    ul>

    Researchers will compare TOP-N53 solution in different strengths to a placebo (a look-alike substance that contains no drug) to see if TOP-N53 works to affect the aspects of the illness listed above.

    • 0 views
    • 13 Jun, 2025
    • 3 locations
    Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis (TOP-N53-02)  

    ul>

    Researchers will compare TOP-N53 solution in different strengths to a placebo (a look-alike substance that contains no drug) to see if TOP-N53 works to affect the aspects of the illness listed above.

    • 0 views
    • 28 May, 2025
    • 1 location
    Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of Remdesivir (GS-5734 ) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)

    The primary objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.

    coronavirus infection
    covid-19
    remdesivir
    SARS
    acute respiratory syndrome (sars)
    • 0 views
    • 19 Feb, 2024
    • 8 locations
    Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma

    This is an open-label, multicenter, dose-escalation phase 1 study to determine the Safety and Efficacy of BZ019 in relapsed or refractory CD19+ B-cell Lymphoma subjects.

    • 0 views
    • 19 Feb, 2024
    • 2 locations
    Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

    The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e., Kasai-operated) or NoK (i.e., patients who …

    direct bilirubin
    colony stimulating factor
    serum direct bilirubin
    cholangiography
    gcsf
    • 0 views
    • 19 Feb, 2024
    • 3 locations
    Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

    Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

    sarcoma
    cancer
    paclitaxel
    bisphosphonate
    biopsy tissue
    • 0 views
    • 19 Feb, 2024
    • 1 location
    A First-in-human Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

    This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.

    body mass index
    • 0 views
    • 19 Feb, 2024
    • 1 location